Fujian Haixi Pharmaceuticals Co Ltd (02637.HK)

Fujian Haixi New Drug Creation Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Fuzhou, Fujian. The company went IPO on 2025-10-20. The Company’s main products include Anbili, Haihuitong, Ruiantuo and Saixifu. The Company’s products are mainly used in digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases, inflammatory diseases, oncology, ophthalmology, respiratory diseases and others. The firm mainly operates its businesses in the domestic market.